Catalent to Open New Clinical Supply Facility in Japan
News Jan 21, 2016
Catalent Pharma Solutions has announced that it is to introduce clinical supply services at its 200,000 sq. ft. cGMP facility in Kakegawa, Japan. The site, which has been providing oral drug development and manufacturing solutions for more than 40 years, will offer clinical supply solutions to meet the needs of both domestic and global clinical trial sponsors.
The facility will provide full-service solutions, including project management and clinical supply management, comparator sourcing, secondary packaging and labeling, clinical storage, distribution, and drug return and destruction. Construction has already begun at the facility and is expected to be fully validated and operational in the second quarter of 2016.
The services it is to provide will complement those from Catalent’s existing footprint in Asia-Pacific, which comprise a full service primary and secondary clinical packaging and storage facility in Shanghai, a secondary packaging and clinical storage facility in Singapore, and an extensive regional depot network.
“Catalent’s site in Kakegawa will play a significant role in serving the market in Japan, the second largest pharmaceutical market worldwide and a key country for new global and domestic clinical trials,” commented Wetteny Joseph, Catalent’s President of Clinical Supply Services.
Joseph continued, “The Asia-Pacific region is a key part of our strategic growth initiatives and our site in Japan adds to Catalent’s overall clinical supply capabilities in the region, where we will continue to make investments necessary to help meet customers’ existing and future clinical trial demands.”
With facilities in the US, UK, Germany, Singapore, and China, and an extended network of over 50 audited depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, that can help to expedite clinical trials and ensure that customers are reliably supplied where and when needed around the globe.
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.READ MORE